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effectiveness, it will be important to evaluate the value of new treatments against 
existing comparators based on clinical and health economic and outcomes research 
evidence. The purpose of this study is to provide a comparative review of the clinical, 
economic, and patient-reported outcomes for selected targeted late-stage NSCLC 
therapies and evaluate pharmacoeconomic trends. METHODS: Sixteen targeted thera-
pies, currently approved or late pipeline, were identiﬁed for inclusion herein. A sys-
tematic review of peer-reviewed literature for Phase III studies and US pharmacoeconomic 
evaluations in support of these products was conducted using PubMed, related- 
articles, and ancestral searches. To capture preliminary/recent studies, conference 
proceedings from clinical and pharmacoeconomic research conferences were hand-
searched. An extraction grid was built to record key comparable attributes of each 
study type (e.g., study origin, methods and results) and identify trends in health eco-
nomic evidence platforms. RESULTS: We identiﬁed 70 original clinical, economic or 
patient-reported outcomes evaluations that met the inclusion/exclusion criteria. Phase 
III trials showed that progression free survival (PFS) varied by 1–2 months across 
treatments and most commonly reported adverse events varied, ranging from reports 
of pulmonary hemorrhage (bevacizumab) to rash and diarrhea (erlotinib and geﬁtinib). 
Few economic studies have been conducted in support of current treatments in the 
US; available studies have examined the cost-effectiveness of EGFR testing (erlotinib) 
and budget impact of adding new treatments to plan (erlotinib and pemetrexed). 
Inclusion of quality of life endpoints (e.g., lung cancer scale, FACT-L and EORTC) 
in trials is increasingly common. CONCLUSIONS: To date, few pharmacoeconomic 
evaluations have been published or presented at conferences in support of targeted 
NSCLC agents but current pharmacoeconomic platforms are useful for establishing 
future benchmarks for new entrants.
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OBJECTIVES: Across Europe, health technology assessment and traditional market 
access bodies are requesting more clinical evidence before allowing appropriate market 
access. These raised expectations create an imbalance between what clinical trial 
data is required for market authorization and what is required for market access, 
with greater scrutiny on response rates, QoL and, in particular, overall survival. In 
part to address this imbalance between desired and available data, industry and many 
European payers are considering risk sharing/pay-for-performance. To address this 
growing gap between regulatory and market access requirements, this research seeks 
to provide a better understanding of what payer expectations are and what is driving 
those expectations. METHODS: Oncology analog analysis and targeted primary 
research to assess the success of recently launched oncology value propositions, deﬁned 
by HTA evaluations and market access authorities. Identiﬁcation of risk sharing agree-
ments through secondary research. France and the UK are the primary markets 
researched. RESULTS: This research suggests that HTA and market access bodies 
are becoming more risk adverse and requiring additional data beyond what is needed 
for regulatory approval. CONCLUSIONS: As more and more oncology products 
come to market, offering hope and promises of improved QoL and longer survival, 
payers are increasingly conscious of the budget impact of new, highly valued agents. 
In order to provide access to these products, payers are increasingly raising data 
requirements. However, given the nature of oncology, payers’ expectations vary based 
on the stage of the disease, the level of unmet need, and the number of available 
alternatives.
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OBJECTIVES: To ﬁeld test the EVIDEM framework applying multicriteria decision 
analyses (MCDA) to support health care decisionmaking, with a private health care 
payer in South Africa. METHODS: Liquid based cytology (LBC) for cervical cancer 
screening was selected as a intervention requiring a coverage decision which would 
beneﬁt from an MCDA approach. The matrix included 15 components of decision in 
four domains (quality of evidence, disease, intervention and economics). A synthesized 
health technology assessment report tailored to investigate each component was pre-
pared. The decisionmaking committee estimated the MCDA value of LBC by assigning 
weights and scores for each matrix component. A survey instrument was administered 
to explore validity and outcomes of approach. RESULTS: Value of LBC was estimated 
at 58% of maximum value on the MCDA scale. Main contributors to value were 
relevance and validity of evidence, disease severity and risk reduction. Minor clinical 
improvement and signiﬁcant economic impact contributed little to value. On average, 
86% of committee members indicated that the same 12 components the MCDA matrix 
should always be considered. Non quantiﬁable components of decision were also 
identiﬁed and discussed. A majority of participants reported that the framework 
would improve: understanding of intervention; access to data on quality of evidence; 
consideration of key elements of decision; transparency of the decision; and under-
standability of decision by stakeholders. CONCLUSIONS: The EVIDEM framework 
provides a transparent record of how evidence and values are assessed during the 
decisionmaking process. Further testing and validation is needed to advance MCDA 
approaches in health care decisionmaking.
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BACKGROUND: In allocating resources to improve patient care, two decisions must 
be addressed: 1) whether to issue guidance on the use of a health technology consider-
ing its cost-effectiveness, and 2) whether to invest in the active implementation of such 
guidance (e.g. via education, incentives or regulation), as its clinical use does not neces-
sarily follow. Since these two decisions are related, resource allocation can be based 
on either sequential (1-by-1) or integral analysis. OBJECTIVES: To identify the pre-
ferred approach to the analysis for addressing decisions about issuing and actively 
implementing clinical guidance. APPLICATION: The application relates to the alloca-
tion of resources to metastatic hormone-refractory prostate cancer (mHRPC) in the 
UK. METHODS: An integrated Bayesian approach to decision modeling and evidence 
synthesis is adopted. Evidence on the costs and QALYs of all plausible treatment regi-
mens is combined with estimates of treatment usage and population size. Implementa-
tion costs and effects are assumed to vary between treatment options. Both sequential 
and integral analyses of resource allocation are performed. RESULTS: (preliminary): 
For cost-effectiveness thresholds £25,000–£32,000 per QALY, decisions about how 
best to improve care for mHRPC patients differ between the alternative analytic 
approaches. Based on sequential analysis, MitoxantronePrednisone is deemed cost-
effective, without actively implementing this guidance. An integral analysis reveals that 
active implementation of DocetaxelPrednisone (3 weekly) is the cost-effective option, 
yielding an additional 0.05 QALY per patient. By combining uncertain evidence on 
treatment regimens, their usage and active implementation, allowance is made for all 
uncertainty associated with resource allocation in mHRPC. CONCLUSIONS: For the 
analysis of the related decisions about 1) issuing, and 2) actively implementing clinical 
guidance, an integral approach is preferred over a sequential one. As the application 
in mHRPC demonstrates, integral analysis provides better options for improving 
patient management, more comprehensive insight in decision uncertainty and, conse-
quently, an efﬁcient allocation of resources.
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OBJECTIVES: The aim of this study was to collect comparable and reliable data on 
the chemotherapy regimens in Slovakia during the period 1999–2008. The special 
interest was paid to the trend of antineoplastic agents, endocrine therapy, immunos-
timulants and immunosuppressants usages. METHODS: Data of wholesalers (follow-
ing ATC/DDD), who are legally obliged provide this information to the Slovak 
Institute for Drug Control, was used for the analysis. The results were expressed in 
ﬁnance units (a) and deﬁned daily doses per 1000 inhabitants per day (DID). 
RESULTS: The collected data showed a dramatic increase in chemotherapy from 1999 
to 2008 in term of DID—in 1999 (17.55), in 2003 (30.33) and in 2008 (38.61). We 
can see a signiﬁcant increase in consumption of antineoplastic agents (DID)—in 1999 
(11.75), in 2003 (18.06) and in 2008 (29.77) and a noticeable increase in endocrine 
therapy—in 1999 (1.71), in 2003 (1.49) and in 2008 (2.48). Unstable consumption 
of immunostimulants—in 1999 (3.76), in 2003 (10.15) and in 2008 (5.06), and a 
moderate increase in consumption of immunosuppressants—in 1999 (0.31), in 2003 
(0.62) and in 2008 (1.29) can be seen from this analysis. Results showed a dramatic 
increase in consumptions from the ﬁnancial perspective—antineoplastic agents in 1999 
(a5,440,000), in 2003 (a16,599,000) and in 2008 (a97,915,000), endocrine therapy 
in 1999 (a3,292,000), in 2003 (a6,779,000) and in 2008 (a14,186,000), immunos-
timulants in 1999 (a5,248,000), in 2003 (a15,538,000) and in 2008 (a24,178,000), 
immunosuppressive agents in 1999 (a3,867,000), in 2003 (a8,109,000) and in 2008 
(a28,288,000). CONCLUSIONS: Inseparable components of the Slovak drug policy 
must be viewed realistically with regard to chemotherapy regimens, which cause huge 
ﬁnancial expenditures within the Slovak health care budget.
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OBJECTIVES: To evaluate the relationship between the average out of pocket cost 
(OPC) paid and the total prescription volume (TRx) for oral antineoplastics compared 
to a market basket of commonly utilized oral drugs. Is drug utilization more sensitive 
to OPC changes when there is greater competition and/or when the ailments treated 
by those drugs are less acute? We hypothesized an inverse proportional relationship 
between OPC and TRx. METHODS: We obtained monthly OPC data and TRx 
data from SDI’s VONA and VOPA databases from January 2007-April 2009. We 
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compared eight oral antineoplastics (capecitabine, imatinib, lenalidomide, thalido-
mide, sunitinib, erlotinib, temozolomide, dasatinib) to a market basket of eight com-
monly utilized oral drugs (celecoxib, sitagliptin, rosuvastatin, fenoﬁbrate, ramipril, 
simvastatin, atorvastatin, amlodipine). We calculated the correlation coefﬁcient (r2) 
for the relationships between a drug’s average OPC and its TRx. RESULTS: Two of 
the eight cancer drugs (erlotinib and dasatinib) showed any remarkable correlations 
(r2  0.17 and 0.29, respectively) while the other six all had correlation coefﬁcients 
less than 0.10. Five of the market basket drugs had a correlation coefﬁcient greater 
than 0.10. Four of those had negative correlations between OPC and TRx: simvastatin 
(r2  0.71), sitagliptin (r2  0.64), amlodipine (r2  0.59), atorvastatin (r2  0.14). 
Interestingly, ramipril had a signiﬁcant positive correlation between OPC and TRx (r2 
 0.51). CONCLUSIONS: Antineoplastic utilization appears to be inelastic with 
respect to OPC ﬂuctuations vis-à-vis the chosen market basket. This observation may 
be a function of the severity of disease, the lack of treatment options or both. In con-
trast, changes in OPC for products in the general market basket, notably simvastin 
and sitagliptin, precipitated signiﬁcant changes in drug utilization. Broader treatment 
options and speciﬁcally generic competition may contribute to this ﬁnding. Further 
research is warranted to track these relationships in a prospective, multi-factorial 
manner in order to better infer a cause-effect relationship.
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OBJECTIVES: As an extension of our 2008 study, which demonstrated that clustering 
of oncology speciﬁc resources exceeded the spatial concentration pattern of health 
care services observed in Greece, we analyzed nation–wide data, in order to identify 
and highlight the cross-regional ﬂows of cancer patients to access adequate treatment. 
METHODS: Patient admission and discharge data from public hospitals for the period 
1999–2005 were collected on a regional basis from the National Statistical Service of 
Greece (NSS). Patients with a cancer diagnosis were grouped according to a) place of 
residence and b) place of treatment for the 11 regions of Greece. RESULTS: A signiﬁ-
cant ﬂow of patients was observed towards Attika, the largest urban center and capital 
of Greece, where the number of cancer patients treated exceeded the number of cancer 
patients residing in the region by 48.9%, per year, on average. The reverse pattern 
(negative ﬂow) was observed in Sterea, Ionian Islands, Aegean Islands, Thessaly and 
Thrace, the corresponding percentages being 76.2%, 63.3%, 45.2%, 37.3% and 
27.9%, respectively. For the remaining 5 regions the ﬂows did not exceed o 10%. 
A further analysis based on type of cancer for the Attika region revealed that the 
highest ﬂows, proportionally, according to diagnoses, were observed for melanoma, 
malignant and benign neoplasms of the uterus and Hodgkin’s disease, whereas the 
lowest for benign neoplasms of the skin, the urinary organs and the thyroid. CON-
CLUSIONS: Cross-regional ﬂows of cancer patients to access adequate cancer treat-
ment is in line with the geographical misdistribution of oncology-speciﬁc resources in 
favor of larger urban areas, especially Attika. A fair allocation of resources according 
to population distribution and cancer prevalence, as well as ongoing disease manage-
ment programs at the place of residence, could greatly contribute to improved access 
to oncology services and minimize the socioeconomic burden to patients and their 
carers.
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OBJECTIVES: The Japanese Cancer Control Act took effect in 2007. The objectives 
of the Cancer Control Act are to improve regional cancer care and promote a uni-
formly high level of cancer care nationwide. To achieve these goals, the Act speciﬁes 
that all 47 prefectural governments in Japan formulate cancer control programs 
(CCPs) by 2008. Our study aimed to systematically review the CCPs of 45 of Japan’s 
prefectural governments that were formulated by January 2009 and then compare 
them to the programs that have been established in the West. METHODS: Six areas 
of the CCPs of 45 of Japan’s prefectural governments were systematically reviewed: 
“prevention,” “treatment,” and “palliative care.” etc. Parameters assessed included 
whether the proportion of smokers was being investigated, whether the numbers of 
radiation therapy and chemotherapy specialists engaged in cancer therapy were 
known, and whether the number of palliative care beds was known (a total of 224 
parameters). RESULTS: The highest-rated plan overall received a score of 65.8, and 
the lowest a score of 35.3. Of the 45 plans, 21 (47%) established target values without 
actually determining the current proportion of minors who smoke, 25 (56%) did not 
investigate the numbers of specialists in cancer therapy. In addition, areas in which 
Japan is similar to the UK and the US, which operate CCPs on a national level, were 
clariﬁed. CONCLUSIONS: It was found that not a few of the programs rest on shaky 
foundations and are of questionable implementability. An international comparison 
revealed that Britain’s NHS Cancer Plan has achieved a reduction in the smoking rate 
and increased anticancer drug use, and the United States’ NCCCP has produced results 
by supporting the CCPs of virtually all 50 states, achievements that should serve as a 
model for Japan.
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OBJECTIVES: Cancer screening is essential component of national cancer control 
programmes. Screening programmes for breast, colorectal and cervical cancers are 
efﬁcacious in decreasing cancer mortality and are recommended by the EU Council 
to all member states. For screening to be effective, delivery as organized programme 
is highly recommended. Vital part of organized programme is performance monitoring 
employing data on all screening tests performed. In absence of dedicated data collec-
tion system, alternative ways of performance monitoring should be employed. Our 
objective is to demonstrate feasibility of performance monitoring using administrative 
data. METHODS: This was a cross-sectional study to ascertain coverage by cancer 
screening tests in Czech population in years 2000–2007. Administrative data from 
health insurance companies were collected by the National Reference Centre. Aggre-
gated data were collected on procedures associated with cancer screening programmes, 
in particular screening mammography, FOBT, and gynaecology preventive examina-
tion. RESULTS: Most reliable data from years 2006–2007 were used for coverage 
estimation. In the two-year period, 745,725 women aged 45–69 years (43.5 %) 
underwent mammography screening, compared to 754,147 records in dedicated breast 
cancer screening database. In the same period, 593,512 men and women aged over 
50 years (16.0 %) underwent colorectal cancer screening. In 2007, gynaecology pre-
ventive examination was attended by 1,083,256 women (40.9 % of population aged 
25–59 years). CONCLUSIONS: Performance monitoring using administrative data is 
feasible, which was demonstrated by ascertaining screening test coverage. Concor-
dance between administrative data and data in dedicated breast cancer screening 
database is excellent. Due to absence of actual data on population coverage in other 
screening programmes, administrative data is the only available and reliable source of 
information on access to programme by citizens in all regions. Future use of individual 
administrative data could help us to evaluate various other screening process compo-
nents associated with its effectiveness, safety and cost-effectiveness.
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OBJECTIVES: The cost of drugs for cancer treatment continues to increase, especially 
with the addition of monoclonal antibodies and other targeted therapies to standard 
cancer treatment regimens. The purpose of this study was to examine the pharmaceuti-
cal expenditure growth in anticancer drugs in Catalonia between 2003 and 2007. 
METHODS: Data from the Pharmaceutical Care and Complementary Beneﬁts data-
base from the Catalan Health Service was used. This database contains information 
on all drugs dispensed in the outpatient setting in public hospitals. Drug expenditure 
was not adjusted for inﬂation and results are expressed in nominal terms. RESULTS: 
From 2003 to 2007, total drug expenditure (TDE) grew at an average annual rate of 
13.4%. During this period mean average growth rate for total anticancer drug expen-
diture (TACDE) was 46.1% increasing from 24,8 million Euros in 2003 to a111.6 
million in 2007. TACDE as percentage of TDE increased over the 5-year period from 
9% in 2003 to 22.6% in 2007. Considerable variation in growth of TACDE was 
observed across regions and hospitals. Six drugs (trastuzumab, imatinib, docetaxel, 
oxaliplatin, rituximab and paclitaxel) accounted for 67% of TACDE. The number of 
patients receiving anticancer drugs and the number of dispensed drugs increased by 
29,13% and 34,2%, respectively. Per patient anticancer drug expenditure increased 
from a3.896/patient in 2003 and a6.220/patient in 2007. Information in diagnosis 
was not available and analyses per type of cancer could not be performed. CONCLU-
SIONS: Anticancer drug expenditure in the outpatient setting has been increasingly 
growing during the study period. Both the volume of drug use and the entry of new 
drugs (typically introduced to the market at higher prices) seem to be explanatory 
factors determining drug spending trends in Catalonia. A more comprehensive 
approach to the use of anticancer drugs by type of cancer is of high importance.
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OBJECTIVES: To analyse key differences between the recently negotiated Pharma-
ceutical Price Regulation Scheme (PPRS) and previous schemes. Understanding the 
implications of these changes is important for the pharmaceutical industry and pricing 
and reimbursement (P&R) activities, particularly when considering the application of 
risk-sharing. METHODS: The new and old versions of the PPRS were compared 
across several dimensions: 1) price cuts; 2) price and proﬁt controls; 3) new initiatives; 
and 4) incentives. In particular, the recent introduction of “patient access schemes” 
(PASs) was examined. Recent risk-sharing agreements (Velcade and Lucentis) were 
presented as case studies. To provide an international perspective and cross-market 
comparison, the analysis also considered examples of risk-sharing schemes as used in 
